Last updated: March 9, 2026
What is the Drug Identified by NDC 69452-0206?
NDC 69452-0206 corresponds to Firdapse (amifampridine), developed by Jacobus Pharmaceutical. It is approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS), a rare neuromuscular disorder.
Market Overview
Patient Population
- LEMS prevalence is approximately 3.4 per million individuals.
- Estimated US patients: 1,000–2,000.
- Small patient base compared to common neuromuscular conditions.
Competitive Landscape
- Firdapse is the only FDA-approved therapy for LEMS.
- Off-label treatments include 3,4-DAP, a compounded drug used off-label but with variable availability and regulation.
- The commercial environment is limited, but patent protections and exclusive rights position Firdapse as the market leader.
Regulatory Status
- Approved by FDA in 2018 under a special protocol assessment.
- Market exclusivity extends until at least 2033 unless challenged by patent expiration or regulatory changes.
Pricing Details
Current Price Points
- Wholesale acquisition cost (WAC): Approximately $375 per 10 mg tablet.
- Typical prescribed dose: 10–30 mg three times daily.
- Monthly treatment cost per patient: around $3,375 to $10,125.
Price Drivers
- No generic equivalents as of 2023.
- Pricing supported by orphan drug status, limited competition, and high R&D costs recouped.
- Variability arises from different insurance coverage policies and patient copay assistance programs.
Price Trends and Projections
| Year |
Price Change |
Notes |
| 2018 |
N/A |
Initial launch at ~$375 per tablet. |
| 2020 |
Stable |
No significant change in pricing. |
| 2022 |
Slight increase (~3%) |
Possible cost adjustments for inflation and manufacturing. |
| 2023 |
Stable |
Market factors remain steady with no generics. |
Future Pricing Outlook (2024–2028)
- Expect stability due to lack of competition.
- Potential price increases linked to inflation, manufacturing costs, or policy adjustments.
- No imminent generic entry anticipated before patents expire in 2033.
Market Growth and Revenue Projections
Key Assumptions
- Patient base: 1,500 patients in the US.
- Annual dosing: 30 mg per day (~3 tablets per day).
- Price per tablet: $375.
- Revenue per patient: ~$3,375/month or ~$40,500/year.
Revenue Forecasts
| Year |
Estimated US Revenue |
Notes |
| 2023 |
~$61 million |
Based on current prices and patient estimates. |
| 2024 |
~$62 million |
Slight price stability assumed. |
| 2025 |
~$63 million |
Minor increases possible. |
| 2026 |
~$65 million |
Continued market presence. |
| 2027 |
~$66 million |
No significant shifts expected. |
Global Market Potential
- Limited data on international approvals.
- Countries like EU and Canada may adopt similar pricing, but regulatory and reimbursement dynamics vary, potentially reducing market size.
Risks and Opportunities
Risks
- Price regulation initiatives targeting orphan drugs.
- Patent challenges or litigation reducing exclusivity.
- Potential entry of biosimilar or generic competitors post-2033.
Opportunities
- Expanded indications or label expansions.
- Launch in additional markets with favorable reimbursement policies.
- Price increases based on inflation and supply chain costs.
Key Takeaways
- NDC 69452-0206 (Firdapse) is a monotherapy for LEMS with limited competition.
- Current US price per tablet is approximately $375, leading to annual revenues estimated at over $60 million.
- Market growth remains constrained due to the rarity of LEMS but benefits from high pricing supported by orphan drug status.
- No immediate price reductions expected before patent expiry in 2033.
- Future revenue growth will depend on market expansion, regulatory environment, and potential price adjustments.
FAQs
1. When will generic versions of Firdapse become available?
Post-2033, assuming patent expiration. No generics are expected before then.
2. How does the price of Firdapse compare internationally?
Pricing varies significantly, often lower in countries with national health systems or price regulation, but data is limited.
3. Are there significant insurance or access barriers?
Yes. High cost may limit access, though copay assistance programs mitigate some barriers.
4. Is the market for Firdapse growing?
Growth is limited by the small patient population; any expansion depends on label extensions or new indications.
5. What factors could influence future pricing?
Inflation, manufacturing costs, regulatory changes, and policy interventions aimed at reducing orphan drug prices.
References
[1] U.S. Food and Drug Administration. (2018). Firdapse (amifampridine) approval announcement.
[2] Jacobus Pharmaceutical. (2023). Firdapse prescribing information.
[3] IQVIA. (2022). US pharmaceutical market data.
[4] Orphan Drug Designations & Approvals. (2022). FDA.
Note: Data is accurate as of early 2023; market conditions may shift.
